Abu Dhabi, UAE — The long-standing debate as to when to start anticoagulation in patients with an acute ischemic stroke and atrial fibrillation (AF) looks as though it’s settled. Results of the ...

The American College of Cardiology issued a 2026 scientific statement on direct oral anticoagulants for the prevention of thrombotic events.

Recommendations around dosing, duration, and patient-specific options are woven into the fabric of the scientific statement.

The risk for death goes up for patients with atrial fibrillation (AF) who are put on direct oral anticoagulants (DOAC) at dosages other than those approved for stroke prevention, whether higher or ...

In older patients with atrial fibrillation (AF), apixaban seems to improve outcomes relative to warfarin regardless of frailty status, whereas other direct oral anticoagulants (DOACs) appear ...

To analyze the primary outcomes, DOAC users were matched 1:1 without replacement to a warfarin user. The primary effectiveness outcome was a composite of ischemic stroke or SE. Primary safety outcome ...

Swedish cohort study shows 13% (95% CI, 2-22%) lower risk of kidney function decline or kidney failure and 12% (95% CI, 3-20%) lower risk of acute kidney injury with use of direct oral anticoagulants ...

The direct oral anticoagulants edoxaban, apixaban, rivaroxaban and dabigatran have been recently approved for the treatment of non-valvular atrial fibrillation The new direct oral anticoagulants ...

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma. Safety and efficacy outcomes in immune checkpoint inhibitor (ICI) ...

In 2017, we have the advantage of, having available to us, 4 large clinical trials. All of the phase IV studies that have been published over the last few years review the use of novel oral ...